S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.51
+1.83
+10.97%
FDMT · 4D Molecular Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
4D Molecular Therapeutics Inc (FDMT)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$12.61
-0.51
(-3.93%)
● At close: October 21 at 4:00:00 PM EDT
$12.50
-0.12
(-0.95%)
Pre-Market:
4:00:02 AM EDT
DAY'S RANGE
$12.61
$12.61
$13.42
52-WEEK RANGE
$12.61
$6.96
$16.93
What's happening
- FDMT is down 3.93% today, trading at $12.61. — Live quote
- Volume today (78,449) is well below its 3-month average of 968,970. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-1.04 actual vs. $-1.04 estimated (-0.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 11
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (18 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
FDMT
+74.67%
vs S&P 500
+61.89%
1-YEAR RETURN
FDMT
+16.24%
vs S&P 500
+1.68%
6-MONTH RETURN
FDMT
+30.22%
3-MONTH RETURN
FDMT
+15.16%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.04
Est. $-1.04
MISS -0.3%
2026-04-26 (Q1 2026)
$-1.01
Est. $-1.01
BEAT +0.2%
2026-01-26 (Q4 2025)
$0.43
Est. $-0.78
BEAT +155.3%
2025-10-26 (Q3 2025)
$-1.01
Est. $-1.00
MISS -1.2%
Valuation Measures & Ratios
Enterprise Value4$672.9M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)7.87
Price / Book71.71
EV4 / Revenue7.31
EV4 / EBITDA—
Profit Margin-194.74%
Operating Margin-214.24%
Return on Equity (ROE8)-41.33%
Return on Assets (ROA9)-35.90%
Avg Volume (3M)968,970
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $932.4M | $632.5M | $488.8M | $206.9M | $179.9M |
| P/E | -3.68 | -2.77 | -2.40 | -1.14 | -1.13 |
| Price/Sales | — | — | — | 5592.42 | 3597.90 |
| Price/Book | 2.29 | 1.40 | 1.32 | 0.49 | 0.38 |
| EV/Revenue | — | — | — | 3507.04 | 927.38 |
| ROE | -62.12% | -50.52% | -55.11% | -43.11% | -33.89% |
| ROA | -51.41% | -44.50% | -47.96% | -38.30% | -30.86% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short11,238,611
Change from Prior Settlement-6.41%
% of Float—
Days to Cover (Short Ratio)9.33
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 25106.7% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +16.2%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -194.7%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-20; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on FDMT
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.8M | $3.0M | — | $15.0K | $14.0K | $3.0K | $5.0K | $28.0K |
| Operating income | -$77.0M | -$73.6M | -$61.2M | -$59.5M | -$53.6M | -$51.1M | -$42.5M | -$38.1M |
| Net income | -$72.9M | -$68.8M | -$56.9M | -$54.7M | -$48.0M | -$43.8M | -$35.0M | -$32.4M |
| EPS (diluted) | $-1.04 | $-1.01 | $-1.01 | $-0.98 | $-0.86 | $-0.79 | $-0.63 | $-0.66 |
| EPS (basic) | $-1.04 | $-1.01 | $-1.01 | $-0.98 | $-0.86 | $-0.79 | $-0.63 | $-0.66 |
| Operating margin | -$2.0K | -$2.4K | — | -$396.4K | -$383.0K | -$1.7M | -$849.1K | -$136.2K |
| Net margin | -$1.9K | -$2.3K | — | -$364.4K | -$342.7K | -$1.5M | -$699.1K | -$115.7K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $492.6M | $512.9M | $566.7M | $424.0M | $473.6M | $515.7M | $560.4M | $604.0M |
| Total liabilities | $85.0M | $61.1M | $61.0M | $55.0M | $52.7M | $46.0M | $49.8M | $51.1M |
| Stockholders' equity | $407.7M | $451.8M | $505.7M | $369.0M | $420.9M | $469.7M | $510.6M | $552.9M |
| Total current assets | $383.0M | $405.4M | $413.1M | $312.4M | $303.3M | $332.6M | $434.9M | $510.8M |
| Total current liabilities | $47.7M | $43.4M | $44.0M | $37.1M | $34.7M | $26.9M | $29.1M | $29.5M |
| Cash & equivalents | $70.4M | $72.5M | $60.2M | $48.6M | $77.2M | $133.5M | $149.3M | $187.5M |
| Marketable securities (current) | $291.0M | $318.4M | $342.4M | $256.5M | $216.1M | $187.9M | $275.5M | $314.4M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Marketable securities (non-current) | $69.3M | $66.7M | $111.4M | $67.2M | $123.8M | $137.0M | $80.6M | $48.8M |
| Property, plant & equipment | $12.4M | $13.6M | $14.9M | $16.2M | $17.5M | $18.7M | $19.5M | $19.9M |
| Other non-current assets | $11.4M | $9.9M | $9.2M | $9.4M | $9.4M | $7.0M | $4.3M | $2.9M |
| Accounts payable | $12.5M | $14.7M | $11.2M | $6.9M | $8.7M | $4.2M | $4.4M | $2.9M |
| Accrued liabilities | $25.4M | $22.9M | $26.9M | $24.2M | $19.2M | $16.2M | $18.9M | $21.4M |
| Deferred revenue (current) | $360.0K | $360.0K | $360.0K | $360.0K | $1.1M | $866.0K | $257.0K | $35.0K |
| Long-term debt | $19.6M | — | $0 | — | — | — | — | — |
| Other non-current liabilities | $101.0K | $121.0K | $138.0K | $144.0K | $161.0K | $177.0K | $193.0K | $196.0K |
| Common stock & paid-in capital | $6.0K | $5.0K | $6.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K |
| Retained earnings | -$858.0M | -$785.1M | -$716.3M | -$735.7M | -$678.8M | -$624.2M | -$576.2M | -$526.5M |
| Accumulated other comprehensive income (loss) | -$446.0K | -$180.0K | $727.0K | $671.0K | $337.0K | $332.0K | $229.0K | $1.1M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$70.0M | -$68.1M | $28.6M | -$46.5M | -$43.4M | -$47.8M | -$45.9M | -$29.4M |
| Investing cash flow | $25.5M | $68.9M | -$128.8M | $17.8M | -$13.9M | $31.9M | $7.1M | $27.3M |
| Financing cash flow | $42.3M | $11.5M | $112.0M | $116.0K | $862.0K | $0 | $601.0K | $568.0K |
| Free cash flow | -$70.1M | — | $28.6M | -$46.4M | -$43.4M | -$48.4M | -$46.8M | -$31.2M |
| Capital expenditures | $55.0K | — | -$70.0K | -$91.0K | $66.0K | $631.0K | $949.0K | $1.8M |
| Share-based compensation | $5.9M | $4.5M | $5.6M | $4.5M | $5.0M | $7.0M | $7.6M | $6.5M |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in accounts payable | -$4.1M | $3.5M | $4.3M | -$1.8M | $4.5M | -$235.0K | $1.5M | -$508.0K |
| Purchases of investments | $62.0M | $33.5M | $178.1M | $15.2M | $115.4M | $134.1M | $57.8M | $35.8M |
| Debt issued | $19.3M | — | — | — | $0 | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $85.2M | $37.0K | $20.7M | $3.1M | $18.0M |
| Operating income | -$159.5M | -$187.8M | -$112.9M | -$110.0M | -$71.3M |
| Net income | -$140.1M | -$160.9M | -$100.8M | -$107.5M | -$71.3M |
| EPS (diluted) | $-2.42 | $-2.98 | $-2.58 | $-3.32 | $-2.57 |
| EPS (basic) | $-2.42 | $-2.98 | $-2.58 | $-3.32 | $-2.57 |
| Operating margin | -$187 | -$507.7K | -$545 | -$3.5K | -$395 |
| Net margin | -$164 | -$434.8K | -$487 | -$3.4K | -$395 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $566.7M | $560.4M | $339.9M | $261.8M | $353.5M |
| Total liabilities | $61.0M | $49.8M | $32.1M | $30.5M | $34.4M |
| Stockholders' equity | $505.7M | $510.6M | $307.8M | $231.3M | $319.1M |
| Total current assets | $413.1M | $434.9M | $296.6M | $220.5M | $256.3M |
| Total current liabilities | $44.0M | $29.1M | $19.0M | $15.7M | $16.3M |
| Cash & equivalents | $60.2M | $149.3M | $249.1M | $52.4M | $153.0M |
| Marketable securities (current) | $342.4M | $275.5M | $39.1M | $161.2M | $94.8M |
| Accounts receivable | — | — | — | $0 | $47.0K |
| Marketable securities (non-current) | $111.4M | $80.6M | $11.0M | $4.9M | $67.7M |
| Property, plant & equipment | $14.9M | $19.5M | $20.1M | $22.3M | $14.4M |
| Other non-current assets | $9.2M | $4.3M | $684.0K | $1.1M | $602.0K |
| Accounts payable | $11.2M | $4.4M | $3.5M | $3.3M | $4.8M |
| Accrued liabilities | $26.9M | $18.9M | $12.0M | $8.9M | $7.7M |
| Deferred revenue (current) | $360.0K | $257.0K | $273.0K | $884.0K | $2.6M |
| Other non-current liabilities | $138.0K | $193.0K | $248.0K | $21.0K | $120.0K |
| Common stock & paid-in capital | $6.0K | $5.0K | $4.0K | $3.0K | $3.0K |
| Retained earnings | -$716.3M | -$576.2M | -$415.3M | -$314.5M | -$207.0M |
| Accumulated other comprehensive income (loss) | $727.0K | $229.0K | $16.0K | -$1.2M | -$423.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$109.1M | -$134.6M | -$75.8M | -$86.7M | -$69.1M |
| Investing cash flow | -$93.0M | -$302.4M | $115.7M | -$17.1M | -$172.7M |
| Financing cash flow | $113.0M | $337.2M | $156.8M | $3.1M | $118.1M |
| Free cash flow | -$109.6M | -$138.4M | -$78.6M | -$98.2M | -$78.2M |
| Capital expenditures | $536.0K | $3.8M | $2.8M | $11.5M | $9.1M |
| Share-based compensation | $22.0M | $26.1M | $19.7M | $17.1M | $13.8M |
| Change in accounts receivable | — | — | $0 | -$47.0K | -$1.4M |
| Change in accounts payable | $6.8M | $871.0K | $896.0K | -$1.6M | $2.3M |
| Purchases of investments | $442.8M | $467.7M | $54.8M | $153.3M | $168.6M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding FDMT as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-20 to 2026-10-16
Recent transactions
- Insiders have net sold 423,500 shares over the last 182 days, across 0 purchases and 19 sales.
- Most recent: Bizily Scott (Chief Legal Officer) — Option exercise of 1,635 shares on 2026-10-16.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)423,500 sh(19 txns)
Net Shares-423,500
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Bizily Scott | Chief Legal Officer | Option exercise | 2026-10-16 | 1,635 |
| Kirn David | See Remarks | Open market sale | 2026-10-05 | 58,061 |
| Gupta Ashoo | VP, Finance and Controller | Option exercise | 2026-03-20 | 865 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-16 | Bizily Scott | Chief Legal Officer | Option exercise | 1,635 | $4.14 |
| 2026-10-16 | Bizily Scott | Chief Legal Officer | Open market sale | 1,635 | $12.84 |
| 2026-10-05 | Kirn David | See Remarks | Open market sale | 58,061 | $12.92 |
| 2026-10-05 | Kirn David | See Remarks | Open market sale | 272 | $13.61 |
| 2026-09-16 | Bizily Scott | Chief Legal Officer | Option exercise | 1,635 | $4.14 |
| 2026-09-16 | Bizily Scott | Chief Legal Officer | Open market sale | 1,635 | $13.65 |
| 2026-09-14 | Kirn David | See Remarks | Open market sale | 58,333 | $13.90 |
| 2026-09-01 | Bizily Scott | Chief Legal Officer | Option exercise | 584 | $6.49 |
| 2026-09-01 | Bizily Scott | Chief Legal Officer | Open market sale | 584 | $14.00 |
| 2026-08-19 | Kirn David | See Remarks | Option exercise | 50,000 | $4.14 |
| 2026-08-19 | Kirn David | See Remarks | Open market sale | 43,149 | $15.36 |
| 2026-08-19 | Kirn David | See Remarks | Open market sale | 25,927 | $16.42 |
| 2026-08-17 | Bizily Scott | Chief Legal Officer | Option exercise | 1,635 | $4.14 |
| 2026-08-17 | Bizily Scott | Chief Legal Officer | Open market sale | 1,635 | $12.20 |
| 2026-08-13 | Bizily Scott | Chief Legal Officer | Option exercise | 1,635 | $4.14 |
| 2026-08-13 | Bizily Scott | Chief Legal Officer | Open market sale | 1,635 | $12.00 |
| 2026-08-04 | Kirn David | See Remarks | Open market sale | 26,842 | $10.23 |
| 2026-08-03 | Kirn David | See Remarks | Open market sale | 12,415 | $10.05 |
| 2026-07-10 | Kirn David | See Remarks | Open market sale | 15,283 | $12.01 |
| 2026-07-10 | Kirn David | See Remarks | Open market sale | 442 | $12.84 |
| 2026-07-09 | Kirn David | See Remarks | Open market sale | 42,608 | $12.87 |
| 2026-06-30 | Bizily Scott | Chief Legal Officer | Option exercise | 814 | $4.14 |
| 2026-06-30 | Bizily Scott | Chief Legal Officer | Option exercise | 5,752 | $6.49 |
| 2026-06-30 | Bizily Scott | Chief Legal Officer | Open market sale | 6,566 | $14.00 |
| 2026-06-23 | Bizily Scott | Chief Legal Officer | Option exercise | 9,810 | $4.14 |
| 2026-06-23 | Bizily Scott | Chief Legal Officer | Open market sale | 9,810 | $12.00 |
| 2026-06-22 | Kirn David | See Remarks | Open market sale | 114,746 | $10.47 |
| 2026-06-01 | Kirn David | See Remarks | Open market sale | 1,922 | $10.02 |
| 2026-03-20 | Gupta Ashoo | VP, Finance and Controller | Option exercise | 865 | — |
| 2026-03-20 | Gupta Ashoo | VP, Finance and Controller | Open market sale | 310 | $8.61 |
| 2026-03-20 | Gupta Ashoo | VP, Finance and Controller | Option exercise | 221 | — |
| 2026-03-20 | Gupta Ashoo | VP, Finance and Controller | Open market sale | 80 | $8.61 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:30 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-20 | 4 | 2026-10-16 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-09-28 | 8-K | 2026-09-28 | View on SEC.gov → |
| 2026-09-22 | 4 | 2026-09-16 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-03 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-08-21 | 4 | 2026-08-19 | View on SEC.gov → |
| 2026-08-17 | 4 | 2026-08-13 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-08-05 | 4 | 2026-08-04 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-08-03 | View on SEC.gov → |
Recent news
Headlines about FDMT (4D Molecular Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day Transcript
Seeking Alpha · 2026-10-21 -
4D Molecular Therapeutics Rings the Nasdaq Stock Market Closing Bell
Nasdaq · 2026-10-21 -
4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day - Slideshow
Seeking Alpha · 2026-10-21 -
Cystic Fibrosis Market Poised for Growth During the Forecast Period (2026-2036) as CFTR Modulators Transform Treatment Landscape | DelveInsight
Yahoo · 2026-10-21 -
Scott Bizily, 4D Molecular Therapeutics CLO, sells $20,993 in stock
Investing.com · 2026-10-21 -
After exercising options, legal chief sells 1,635 shares of 4D Molecular Therapeutics (FDMT).
Stock Titan · 2026-10-20 -
General Motors, Genuine Parts, Steel Dynamics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Benzinga · 2026-10-20 -
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 2026-10-20
No headlines in this category right now — try “All”.